Advertisement

Hallucinations in Neurological Disorders

  • Alessio Di Fonzo
  • Edoardo Monfrini
  • Paola Basilico
  • Andrea Arighi
Chapter

Abstract

Hallucinations are present in many nonpsychiatric subjects. Indeed, these false perceptions are frequently observed in degenerative and non-degenerative neurological disorders. In this chapter, we aim to describe the phenomenology, pathogenesis, and available therapies for hallucinations in these neurological conditions.

References

  1. 1.
    Aleman A, Larøi F. Hallucinations: the science of idiosyncratic perception. Psychiatric Services. 2008;60.10.1037/11751-000.Google Scholar
  2. 2.
    Rasmussen T, Penfield W. Further studies of the sensory and motor cerebral cortex of man. Fed Proc. 1947;6(2):452–60.PubMedGoogle Scholar
  3. 3.
    Kompanje EJ. ‘The devil lay upon her and held her down’. Hypnagogic hallucinations and sleep paralysis described by the Dutch physician Isbrand van Diemerbroeck (1609–1674) in 1664. J Sleep Res. 2008;17(4):464–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Waters F, Blom JD, Dang-Vu TT, Cheyne AJ, Alderson-Day B, Woodruff P, et al. What is the link between hallucinations, dreams, and hypnagogic-hypnopompic experiences? Schizophr Bull. 2016;42(5):1098–109.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Dahmen N, Kasten M. REM-associated hallucinations and sleep paralysis are dependent on body posture. J Neurol. 2001;248(5):423–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Dahmen N, Kasten M, Muller MJ, Mittag K. Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. J Sleep Res. 2002;11(2):179–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheyne JA, Newby-Clark IR, Rueffer SD. Relations among hypnagogic and hypnopompic experiences associated with sleep paralysis. J Sleep Res. 1999;8(4):313–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain. 1998;121(Pt 10):1819–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheyne JA, Rueffer SD, Newby-Clark IR. Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn. 1999;8(3):319–37.PubMedCrossRefGoogle Scholar
  10. 10.
    McNally RJ, Clancy SA. Sleep paralysis, sexual abuse, and space alien abduction. Transcult Psychiatry. 2005;42(1):113–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Hishikawa Y, Nan'no H, Tachibana M, Furuya E, Koida H, Kaneko Z. The nature of sleep attack and other symptoms of narcolepsy. Electroencephalogr Clin Neurophysiol. 1968;24(1):1–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55(2):281–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Fazio—Loeb. Neurologia. 2003.Google Scholar
  14. 14.
    Penney L, Galarneau D. Peduncular hallucinosis: a case report. Ochsner J. 2014;14(3):450–2.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Middleton FA, Strick PL. The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci U S A. 1996;93(16):8683–7.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Spiegel DR, Rivers J, Peglow S. A probable case of peduncular hallucinosis status postthalamic and cerebral peduncle cerebrovascular accident treated successfully with risperidone. J Neuropsychiatry Clin Neurosci. 2014;26(3):E42.PubMedCrossRefGoogle Scholar
  17. 17.
    Cammaroto S, D’Aleo G, Smorto C, Bramanti P. Charles Bonnet syndrome. Funct Neurol. 2008;23(3):123–7.PubMedGoogle Scholar
  18. 18.
    Griffiths TD. Musical hallucinosis in acquired deafness. Phenomenology and brain substrate. Brain. 2000;123(Pt 10):2065–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Lerario A, Ciammola A, Poletti B, Girotti F, Silani V. Charles Bonnet syndrome: two case reports and review of the literature. J Neurol. 2013;260(4):1180–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Golden EC, Josephs KA. Minds on replay: musical hallucinations and their relationship to neurological disease. Brain. 2015;138(Pt 12):3793–802.PubMedCrossRefGoogle Scholar
  21. 21.
    EF C, Marchie A, Norris M. Musical and auditory hallucinations: a spectrum. Psychiatry Clin Neurosci. 2004;58(1):96–8.CrossRefGoogle Scholar
  22. 22.
    Abbott EJ, Connor GB, Artes PH, Abadi RV. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci. 2007;48(3):1416–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Pang L. Hallucinations experienced by visually impaired: Charles Bonnet syndrome. Optom Vis Sci. 2016;93(12):1466–78.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci. 1998;1(8):738–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Eysel UT, Schweigart G, Mittmann T, Eyding D, Qu Y, Vandesande F, et al. Reorganization in the visual cortex after retinal and cortical damage. Restor Neurol Neurosci. 1999;15(2-3):153–64.PubMedGoogle Scholar
  26. 26.
    Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain. 2000;123(Pt 10):2055–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1973;188(2):139–50.PubMedCrossRefGoogle Scholar
  28. 28.
    Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry. 2002;73(5):535–41.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Ukai S, Yamamoto M, Tanaka M, Takeda M. Treatment of typical Charles Bonnet syndrome with donepezil. Int Clin Psychopharmacol. 2004;19(6):355–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet’s syndrome. Lancet. 1996;347(9004):794–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Eperjesi F, Akbarali N. Rehabilitation in Charles Bonnet syndrome: a review of treatment options. Clin Exp Optom. 2004;87(3):149–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Waters WE, O’Connor PJ. Prevalence of migraine. J Neurol Neurosurg Psychiatry. 1975;38(6):613–6.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346(4):257–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996;119(Pt 2):355–61.PubMedCrossRefGoogle Scholar
  35. 35.
    Spranger M, Spranger S, Schwab S, Benninger C, Dichgans M. Familial hemiplegic migraine with cerebellar ataxia and paroxysmal psychosis. Eur Neurol. 1999;41(3):150–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Todd J. The syndrome of Alice in Wonderland. Can Med Assoc J. 1955;73(9):701–4.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Blom JD. Alice in Wonderland syndrome: a systematic review. Neurol Clin Pract. 2016;6(3):259–70.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98(8):4687–92.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Miller EE, Grosberg BM, Crystal SC, Robbins MS. Auditory hallucinations associated with migraine: case series and literature review. Cephalalgia. 2015;35(10):923–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Schreier HA. Auditory hallucinations in nonpsychotic children with affective syndromes and migraines: report of 13 cases. J Child Neurol. 1998;13(8):377–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Lippman CW. Certain hallucinations peculiar to migraine. J Nerv Ment Dis. 1952;116(4):346–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Fuller GN, Guiloff RJ. Migrainous olfactory hallucinations. J Neurol Neurosurg Psychiatry. 1987;50(12):1688–90.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Wolberg FL, Ziegler DK. Olfactory hallucination in migraine. Arch Neurol. 1982;39(6):382.PubMedCrossRefGoogle Scholar
  44. 44.
    Morrison DP. Abnormal perceptual experiences in migraine. Cephalalgia. 1990;10(6):273–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003;349(13):1257–66.PubMedCrossRefGoogle Scholar
  47. 47.
    Wieser HG. Depth recorded limbic seizures and psychopathology. Neurosci Biobehav Rev. 1983;7(3):427–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Chen C, Shih YH, Yen DJ, Lirng JF, Guo YC, Yu HY, et al. Olfactory auras in patients with temporal lobe epilepsy. Epilepsia. 2003;44(2):257–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Hausser-Hauw C, Bancaud J. Gustatory hallucinations in epileptic seizures. Electrophysiological, clinical and anatomical correlates. Brain. 1987;110(Pt 2):339–59.PubMedCrossRefGoogle Scholar
  50. 50.
    Baldeweg T, Spence S, Hirsch SR, Gruzelier J. Gamma-band electroencephalographic oscillations in a patient with somatic hallucinations. Lancet. 1998;352(9128):620–1.PubMedCrossRefGoogle Scholar
  51. 51.
    Panayiotopoulos CP. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J Neurol Neurosurg Psychiatry. 1999;66(4):536–40.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Taylor I, Scheffer IE, Berkovic SF. Occipital epilepsies: identification of specific and newly recognized syndromes. Brain. 2003;126(Pt 4):753–69.PubMedCrossRefGoogle Scholar
  53. 53.
    Salanova V, Andermann F, Olivier A, Rasmussen T, Quesney LF. Occipital lobe epilepsy: electroclinical manifestations, electrocorticography, cortical stimulation and outcome in 42 patients treated between 1930 and 1991. Surgery of occipital lobe epilepsy. Brain. 1992;115(Pt 6):1655–80.PubMedCrossRefGoogle Scholar
  54. 54.
    Williamson PD, Boon PA, Thadani VM, Darcey TM, Spencer DD, Spencer SS, et al. Parietal lobe epilepsy: diagnostic considerations and results of surgery. Ann Neurol. 1992;31(2):193–201.PubMedCrossRefGoogle Scholar
  55. 55.
    Sveinbjornsdottir S, Duncan JS. Parietal and occipital lobe epilepsy: a review. Epilepsia. 1993;34(3):493–521.PubMedCrossRefGoogle Scholar
  56. 56.
    Dewhurst K, Pearson J. Visual hallucinations of the self in organic disease. J Neurol Neurosurg Psychiatry. 1955;18(1):53–7.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Ionasescu V. Paroxysmal disorders of the body image in temporal lobe epilepsy. Acta Psychiatr Scand. 1960;35:171–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Fish DR, Gloor P, Quesney FL, Olivier A. Clinical responses to electrical brain stimulation of the temporal and frontal lobes in patients with epilepsy. Pathophysiological implications. Brain. 1993;116(Pt 2):397–414.PubMedCrossRefGoogle Scholar
  59. 59.
    Caplan JP, Epstein LA, Stern TA. Consultants’ conflicts: a case discussion of differences and their resolution. Psychosomatics. 2008;49(1):8–13.PubMedCrossRefGoogle Scholar
  60. 60.
    Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–120.PubMedCrossRefGoogle Scholar
  61. 61.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington, DC: APA; 2013.CrossRefGoogle Scholar
  62. 62.
    Holden B, Gitlesen JP. The association between severity of intellectual disability and psychiatric symptomatology. J Intellect Disabil Res. 2004;48(Pt 6):556–62.PubMedCrossRefGoogle Scholar
  63. 63.
    Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet. 1999;354(9174):233–42.PubMedCrossRefGoogle Scholar
  64. 64.
    Cooper SA, Smiley E, Morrison J, Allan L, Williamson A, Finlayson J, et al. Psychosis and adults with intellectual disabilities. Prevalence, incidence, and related factors. Soc Psychiatry Psychiatr Epidemiol. 2007;42(7):530–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56(10):940–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.PubMedCrossRefGoogle Scholar
  67. 67.
    Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.PubMedCrossRefGoogle Scholar
  68. 68.
    Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer’s disease: review of the brain decade. Psychosomatics. 2003;44(5):388–401.PubMedCrossRefGoogle Scholar
  69. 69.
    Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11):2022–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Burghaus L, Eggers C, Timmermann L, Fink GR, Diederich NJ. Hallucinations in neurodegenerative diseases. CNS Neurosci Ther. 2012;18(2):149–59.PubMedCrossRefGoogle Scholar
  71. 71.
    Matsumoto N, Ikeda M, Fukuhara R, Shinagawa S, Ishikawa T, Mori T, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23(4):219–24.PubMedCrossRefGoogle Scholar
  72. 72.
    Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA. Psychosis in Alzheimer’s disease. Biol Psychiatry. 2014;75(7):542–52.PubMedCrossRefGoogle Scholar
  73. 73.
    Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57(12):1165–73.PubMedCrossRefGoogle Scholar
  74. 74.
    Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58(6):907–11.PubMedCrossRefGoogle Scholar
  75. 75.
    Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, et al. Genome-wide association study of Alzheimer’s disease with psychotic symptoms. Mol Psychiatry. 2012;17(12):1316–27.PubMedCrossRefGoogle Scholar
  76. 76.
    Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, et al. Psychosis and aggression in Alzheimer’s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71(6):777–9.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55(10):1335–40.PubMedCrossRefGoogle Scholar
  78. 78.
    Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378–84.PubMedCrossRefGoogle Scholar
  79. 79.
    Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, et al. Hyperphosphorylated tau is elevated in Alzheimer’s disease with psychosis. J Alzheimers Dis. 2014;39(4):759–73.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Mendez MF, Lauterbach EC, Sampson SM, ANPA Committee on Research. An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci. 2008;20(2):130–49.PubMedCrossRefGoogle Scholar
  81. 81.
    Blanc F, Noblet V, Philippi N, Cretin B, Foucher J, Armspach JP, et al. Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. PLoS One. 2014;9(12):e114774.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Lai MK, Lai OF, Keene J, Esiri MM, Francis PT, Hope T, et al. Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57(5):805–11.PubMedCrossRefGoogle Scholar
  83. 83.
    Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170–8.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Tang-Wai DF, Drubach DA, et al. Visual hallucinations in posterior cortical atrophy. Arch Neurol. 2006;63(10):1427–32.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Suarez-Gonzalez A, Crutch SJ, Franco-Macias E, Gil-Neciga E. Neuropsychiatric symptoms in posterior cortical atrophy and Alzheimer disease. J Geriatr Psychiatry Neurol. 2016;29(2):65–71.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553–63.PubMedCrossRefGoogle Scholar
  87. 87.
    Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.PubMedCrossRefGoogle Scholar
  88. 88.
    Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996;14(2):317–35.PubMedCrossRefGoogle Scholar
  89. 89.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc. 1991;39(7):708–16.PubMedCrossRefGoogle Scholar
  91. 91.
    Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(4):434–40.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53(12):1265–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733–45.PubMedCrossRefGoogle Scholar
  94. 94.
    Asaad G, Shapiro B. Hallucinations: theoretical and clinical overview. Am J Psychiatry. 1986;143(9):1088–97.PubMedCrossRefGoogle Scholar
  95. 95.
    Fenelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson’s disease. J Neurol. 2002;249(12):1699–703.PubMedCrossRefGoogle Scholar
  96. 96.
    Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533–5.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: ‘between a rock and a hard place’. Int Rev Psychiatry. 2000;12(4):319–34.CrossRefGoogle Scholar
  98. 98.
    Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66(1):93–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Shergill SS, Murray RM, McGuire PK. Auditory hallucinations: a review of psychological treatments. Schizophr Res. 1998;32(3):137–50.PubMedCrossRefGoogle Scholar
  100. 100.
    Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55(7):969–78.PubMedCrossRefGoogle Scholar
  101. 101.
    Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology. 1993;43(12 Suppl 6):S47–52.PubMedGoogle Scholar
  102. 102.
    Auzou P, Ozsancak C, Hannequin D, Moore N, Augustin P. Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol Scand. 1996;94(5):329–36.PubMedCrossRefGoogle Scholar
  103. 103.
    The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–63.CrossRefGoogle Scholar
  104. 104.
    de la Chapelle A, Kari C, Nurminen M, Hernberg S. Clozapine-induced agranulocytosis. A genetic and epidemiologic study. Hum Genet. 1977;37(2):183–94.PubMedCrossRefGoogle Scholar
  105. 105.
    Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996;47(4):1085–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52(5):438–45.PubMedCrossRefGoogle Scholar
  107. 107.
    Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology. 1998;50(4):1195–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson’s disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998;21(5):285–8.PubMedGoogle Scholar
  109. 109.
    Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995;56(12):556–9.PubMedGoogle Scholar
  111. 111.
    Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2000;12(3):364–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):594–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord. 2000;15(6):1230–7.PubMedCrossRefGoogle Scholar
  114. 114.
    Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–63.PubMedCrossRefGoogle Scholar
  115. 115.
    Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. 2006;29(4):215–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006;253(2):171–5.PubMedCrossRefGoogle Scholar
  117. 117.
    Dewey RB Jr, O’Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology. 2000;55(11):1753–4.PubMedCrossRefGoogle Scholar
  118. 118.
    Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology. 1995;12(1):39–45.PubMedGoogle Scholar
  119. 119.
    Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67(4):416–21.PubMedCrossRefGoogle Scholar
  120. 120.
    Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–92.PubMedCrossRefGoogle Scholar
  121. 121.
    Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1985;48(5):413–21.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253(2):242–7.PubMedCrossRefGoogle Scholar
  123. 123.
    Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21(11):1899–907.PubMedCrossRefGoogle Scholar
  124. 124.
    Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18.PubMedCrossRefGoogle Scholar
  125. 125.
    Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708–12.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934–9.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561–6.PubMedCrossRefGoogle Scholar
  128. 128.
    McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med. 1992;22(4):911–22.PubMedCrossRefGoogle Scholar
  130. 130.
    Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology. 1996;47(5):1148–52.PubMedCrossRefGoogle Scholar
  131. 131.
    Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry. 1999;156(7):1039–45.PubMedGoogle Scholar
  132. 132.
    Rockwell E, Choure J, Galasko D, Olichney J, Jeste DV. Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. Int J Geriatr Psychiatry. 2000;15(9):819–23.PubMedCrossRefGoogle Scholar
  133. 133.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.PubMedCrossRefGoogle Scholar
  134. 134.
    Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin. 2007;25(3):741–60, viiPubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Ferman TJ, Boeve BF, Smith GE, Silber MH, Lucas JA, Graff-Radford NR, et al. Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. J Int Neuropsychol Soc. 2002;8(7):907–14.PubMedCrossRefGoogle Scholar
  136. 136.
    Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt 2):391–403.PubMedCrossRefGoogle Scholar
  137. 137.
    Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56(5):643–9.PubMedCrossRefGoogle Scholar
  138. 138.
    Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci. 1991;640:197–202.PubMedCrossRefGoogle Scholar
  139. 139.
    McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2004;18(1):94–100.PubMedCrossRefGoogle Scholar
  140. 140.
    Mori E, Ikeda M, Kosaka K, Donepezil DLB, Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41–52.PubMedCrossRefGoogle Scholar
  141. 141.
    McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.PubMedCrossRefGoogle Scholar
  142. 142.
    Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633–7.PubMedCrossRefGoogle Scholar
  143. 143.
    McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673–8.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):549–53.PubMedCrossRefGoogle Scholar
  145. 145.
    Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027–37.PubMedCrossRefGoogle Scholar
  146. 146.
    Terao T, Shimomura T, Izumi Y, Nakamura J. Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies. J Clin Psychiatry. 2003;64(12):1520–1.PubMedCrossRefGoogle Scholar
  147. 147.
    Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13(2):67–73.PubMedCrossRefGoogle Scholar
  148. 148.
    Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.PubMedCrossRefGoogle Scholar
  150. 150.
    Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Tartaglia MC, Kertesz A, Ang LC. Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. Cogn Behav Neurol. 2008;21(2):107–10.PubMedCrossRefGoogle Scholar
  152. 152.
    Shinagawa S, Naasan G, Karydas AM, Coppola G, Pribadi M, Seeley WW, et al. Clinicopathological study of patients with C9ORF72-associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol. 2015;28(2):99–107.PubMedCrossRefGoogle Scholar
  153. 153.
    Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat. 2007;28(9):846–55.PubMedCrossRefGoogle Scholar
  154. 154.
    Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 2010;120(1):33–41.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, et al. Psychosis in frontotemporal dementia. J Alzheimers Dis. 2014;42(2):485–99.PubMedCrossRefGoogle Scholar
  156. 156.
    Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58(5):212–6.PubMedCrossRefGoogle Scholar
  157. 157.
    Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13–9.PubMedCrossRefGoogle Scholar
  158. 158.
    Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400–8.CrossRefGoogle Scholar
  159. 159.
    Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med. 1997;337(25):1821–8.PubMedCrossRefGoogle Scholar
  160. 160.
    Rabinovici GD, Wang PN, Levin J, Cook L, Pravdin M, Davis J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology. 2006;66(2):286–7.PubMedCrossRefGoogle Scholar
  161. 161.
    Heinz A, Schmidt LG, Winterer G, Gerhard L, Przuntek H. Optical and tactile hallucinosis as clinical onset of Creutzfeld-Jakob disease. Nervenarzt. 1995;66(9):712–6.PubMedGoogle Scholar
  162. 162.
    Lueck CJ, McIlwaine GG, Zeidler M. Creutzfeldt-Jakob disease and the eye. II. Ophthalmic and neuro-ophthalmic features. Eye (Lond). 2000;14(Pt 3A):291–301.CrossRefGoogle Scholar
  163. 163.
    Lueck CJ, McIlwaine GG, Zeidler M. Creutzfeldt-Jakob disease and the eye. I. Background and patient management. Eye (Lond). 2000;14(Pt 3A):263–90.CrossRefGoogle Scholar
  164. 164.
    Baiardi S, Capellari S, Ladogana A, Strumia S, Santangelo M, Pocchiari M, et al. Revisiting the Heidenhain variant of Creutzfeldt-Jakob disease: evidence for prion type variability influencing clinical course and laboratory findings. J Alzheimers Dis. 2016;50(2):465–76.PubMedCrossRefGoogle Scholar
  165. 165.
    Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV. Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Arch Neurol. 2009;66(2):208–15.PubMedCrossRefGoogle Scholar
  166. 166.
    Brar HK, Vaddigiri V, Scicutella A. Of illusions, hallucinations and Creutzfeldt-Jakob disease (Heidenhain’s variant). J Neuropsychiatry Clin Neurosci. 2005;17(1):124–6.PubMedCrossRefGoogle Scholar
  167. 167.
    Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, Riedemann C, Windl O, Steinhoff BJ, et al. The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol. 1999;56(1):55–61.PubMedCrossRefGoogle Scholar
  168. 168.
    Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921–5.PubMedCrossRefGoogle Scholar
  169. 169.
    Collinge J. Variant Creutzfeldt-Jakob disease. Lancet. 1999;354(9175):317–23.PubMedCrossRefGoogle Scholar
  170. 170.
    Henry C, Knight R. Clinical features of variant Creutzfeldt-Jakob disease. Rev Med Virol. 2002;12(3):143–50.PubMedCrossRefGoogle Scholar
  171. 171.
    Spencer MD, Knight RS, Will RG. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ. 2002;324(7352):1479–82.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Zeidler M, Johnstone EC, Bamber RW, Dickens CM, Fisher CJ, Francis AF, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997;350(9082):908–10.PubMedCrossRefGoogle Scholar
  173. 173.
    Forloni G, Artuso V, Roiter I, Morbin M, Tagliavini F. Therapy in prion diseases. Curr Top Med Chem. 2013;13(19):2465–76.PubMedCrossRefGoogle Scholar
  174. 174.
    Brown TM, Boyle MF. Delirium. BMJ. 2002;325(7365):644–7.PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008;78(11):1265–70.PubMedGoogle Scholar
  176. 176.
    Jesse S, Brathen G, Ferrara M, Keindl M, Ben-Menachem E, Tanasescu R, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017;135(1):4–16.PubMedCrossRefGoogle Scholar
  177. 177.
    Mirijello A, D’Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353–65.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.PubMedCrossRefGoogle Scholar
  179. 179.
    Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e280.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241–55.PubMedCrossRefGoogle Scholar
  182. 182.
    Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun. 2014;48-49:10–3.PubMedCrossRefGoogle Scholar
  183. 183.
    Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19(1):47–52.PubMedGoogle Scholar
  184. 184.
    Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007;69(7):644–54.PubMedCrossRefGoogle Scholar
  185. 185.
    Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am. 2005;31(2):273–98. viPubMedCrossRefGoogle Scholar
  186. 186.
    Paholpak P, Rangseekajee P, Foocharoen C. Characteristics, treatments and outcome of psychosis in Thai SLE patients. J Psychosom Res. 2012;73(6):448–51.PubMedCrossRefGoogle Scholar
  187. 187.
    Chang HC, Liu CM, Huang WL, Liao SC, Liou MJ, Chang LR. Psychosis and brain hypoperfusion in remitted phase of systemic lupus erythematosus. Psychiatry Clin Neurosci. 2012;66(6):535–6.PubMedCrossRefGoogle Scholar
  188. 188.
    Govoni M, Castellino G, Padovan M, Borrelli M, Trotta F. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus. 2004;13(3):149–58.PubMedCrossRefGoogle Scholar
  189. 189.
    Bonfa E, Chu JL, Brot N, Elkon KB. Lupus anti-ribosomal P peptide antibodies show limited heterogeneity and are predominantly of the IgG1 and IgG2 subclasses. Clin Immunol Immunopathol. 1987;45(1):129–38.PubMedCrossRefGoogle Scholar
  190. 190.
    Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 1981;70(2):240–6.PubMedCrossRefGoogle Scholar
  191. 191.
    Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33(8):1923–32.PubMedCrossRefGoogle Scholar
  192. 192.
    Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med. 1991;81(296):975–84.PubMedCrossRefGoogle Scholar
  193. 193.
    Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol. 2006;253(8):975–84.PubMedCrossRefGoogle Scholar
  194. 194.
    Zhou JY, Xu B, Lopes J, Blamoun J, Li L. Hashimoto encephalopathy: literature review. Acta Neurol Scand. 2017;135(3):285–90.PubMedCrossRefGoogle Scholar
  195. 195.
    Zouboulis CC, Vaiopoulos G, Marcomichelakis N, Palimeris G, Markidou I, Thouas B, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet’s disease in Greece. Clin Exp Rheumatol. 2003;21(4 Suppl 30):S19–26.PubMedGoogle Scholar
  196. 196.
    Al-Araji A, Kidd DP. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.PubMedCrossRefGoogle Scholar
  197. 197.
    Deniz O, Caykoylu A, Vural G, Albayrak Y, Temel S, Aydin I, et al. A case study of neuro-psycho-Behcet’s syndrome presenting with psychotic attack. Clin Neurol Neurosurg. 2009;111(10):877–9.PubMedCrossRefGoogle Scholar
  198. 198.
    Conde-Sendin MA, Amela-Peris R, Aladro-Benito Y, Maroto AA. Current clinical spectrum of neurosyphilis in immunocompetent patients. Eur Neurol. 2004;52(1):29–35.PubMedCrossRefGoogle Scholar
  199. 199.
    Vargas AP, Carod-Artal FJ, Del Negro MC, Rodrigues MP. [Dementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patient]. Arq Neuropsiquiatr. 2000;58(2B):578–82.Google Scholar
  200. 200.
    Taycan O, Ugur M, Ozmen M. Quetiapine vs. risperidone in treating psychosis in neurosyphilis: a case report. Gen Hosp Psychiatry. 2006;28(4):359–61.PubMedCrossRefGoogle Scholar
  201. 201.
    Crozatti LL, de Brito MH, Lopes BN, de Campos FP. Atypical behavioral and psychiatric symptoms: neurosyphilis should always be considered. Autops Case Rep. 2015;5(3):43–7.PubMedPubMedCentralCrossRefGoogle Scholar
  202. 202.
    Kinson RM, Chan LG. Psychiatric symptoms as the sole manifestation of neurosyphilis. J Neuropsychiatry Clin Neurosci. 2013;25(4):E39–40.PubMedCrossRefGoogle Scholar
  203. 203.
    Noblett J, Roberts E. The importance of not jumping to conclusions: syphilis as an organic cause of neurological, psychiatric and endocrine presentations. BMJ Case Rep. 2015;2015.Google Scholar
  204. 204.
    Kambe T, Shimura H, Ueno Y, Nishioka K, Tanaka R, Hattori N, et al. Vivid visual hallucinations manifested as the initial symptom in a patient with neurosyphilis. Psychosomatics. 2013;54(3):284–5.PubMedCrossRefGoogle Scholar
  205. 205.
    Turan S, Emul M, Duran A, Mert A, Ugur M. Effectiveness of olanzapine in neurosyphilis related organic psychosis: a case report. J Psychopharmacol. 2007;21(5):556–8.PubMedCrossRefGoogle Scholar
  206. 206.
    Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007;30(5):631–41.PubMedCrossRefGoogle Scholar
  207. 207.
    DiMagno EP, Lowe JE, Snodgrass PJ, Jones JD. Ornithine transcarbamylase deficiency—a cause of bizarre behavior in a man. N Engl J Med. 1986;315(12):744–7.PubMedCrossRefGoogle Scholar
  208. 208.
    Enns GM, O’Brien WE, Kobayashi K, Shinzawa H, Pellegrino JE. Postpartum “psychosis” in mild argininosuccinate synthetase deficiency. Obstet Gynecol. 2005;105(5 Pt 2):1244–6.PubMedCrossRefGoogle Scholar
  209. 209.
    Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and “schizophrenia”. A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N Engl J Med. 1975;292(10):491–6.PubMedCrossRefGoogle Scholar
  210. 210.
    Pasquier F, Lebert F, Petit H, Zittoun J, Marquet J. Methylenetetrahydrofolate reductase deficiency revealed by a neuropathy in a psychotic adult. J Neurol Neurosurg Psychiatry. 1994;57(6):765–6.PubMedPubMedCentralCrossRefGoogle Scholar
  211. 211.
    Roze E, Gervais D, Demeret S, Ogier de Baulny H, Zittoun J, Benoist JF, et al. Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch Neurol. 2003;60(10):1457–62.PubMedCrossRefGoogle Scholar
  212. 212.
    Rauschka H, Colsch B, Baumann N, Wevers R, Schmidbauer M, Krammer M, et al. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology. 2006;67(5):859–63.PubMedCrossRefGoogle Scholar
  213. 213.
    Baumann N, Masson M, Carreau V, Lefevre M, Herschkowitz N, Turpin JC. Adult forms of metachromatic leukodystrophy: clinical and biochemical approach. Dev Neurosci. 1991;13(4-5):211–5.PubMedCrossRefGoogle Scholar
  214. 214.
    Navon R. Molecular and clinical heterogeneity of adult GM2 gangliosidosis. Dev Neurosci. 1991;13(4-5):295–8.PubMedCrossRefGoogle Scholar
  215. 215.
    Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7(2):119–23.PubMedCrossRefGoogle Scholar
  216. 216.
    Hurowitz GI, Silver JM, Brin MF, Williams DT, Johnson WG. Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings. J Neuropsychiatry Clin Neurosci. 1993;5(1):30–6.PubMedCrossRefGoogle Scholar
  217. 217.
    Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, et al. The adult form of Niemann-Pick disease type C. Brain. 2007;130(Pt 1):120–33.PubMedGoogle Scholar
  218. 218.
    Gutschalk A, Harting I, Cantz M, Springer C, Rohrschneider K, Meinck HM. Adult alpha-mannosidosis: clinical progression in the absence of demyelination. Neurology. 2004;63(9):1744–6.PubMedCrossRefGoogle Scholar
  219. 219.
    Malm D, Pantel J, Linaker OM. Psychiatric symptoms in alpha-mannosidosis. J Intellect Disabil Res. 2005;49(Pt 11):865–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Alessio Di Fonzo
    • 1
  • Edoardo Monfrini
    • 1
  • Paola Basilico
    • 2
  • Andrea Arighi
    • 2
  1. 1.Neurology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Centro Dino Ferrari, Neuroscience Section, Department of Pathophysiology and TransplantationUniversity of MilanMilanItaly
  2. 2.Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino FerrariUniversity of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoMilanItaly

Personalised recommendations